National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Ameloblastoma is not the name you expected.
Ameloblastoma is a rare disorder of the jaw involving abnormal tissue growth. The resulting tumors or cysts are usually not malignant (benign) but the tissue growth may be aggressive in the involved area. On occasion, tissue near the jaws, such as around the sinuses and eye sockets, may become involved as well. The tissues involved are most often those that give rise to the teeth so that ameloblastoma may cause facial distortion. Malignancy is uncommon as are metastases, but they do occur.
Ameloblastoma is characterized by an abnormal growth in the sinus area or jaw, often at the site of the third molar. The tumors or cysts may be aggressive and may spread to the nose, eye socket and skull. It is important for ameloblastoma to be diagnosed and treated early in order to stop growth of the tumors and possible progression to cancer. Although it is uncommon, ameloblastomas have been known to become malignant and spread to other parts of the body, especially to the lungs. The initial surgical treatment must be carefully and scrupulously done to avoid recurrence.
Ameloblastomas do not usually become malignant. There is evidence that tissue is more likely to become malignant if the condition reoccurs after surgery.
The cause of ameloblastoma is not understood. Causes may include injury to the mouth or jaw, infections of the teeth or gums, or inflammation of these same areas. Infections by viruses or lack of protein or minerals in the persons diet are also suspected of causing the growth or development of these tumors. In general, however, scientists do not understand the cause of cysts and tumors, nor the reasons why they can become malignant.
Ameloblastoma is a rare disorder that affects males and females in equal numbers. It affects persons of all ethnic backgrounds and of all age groups.
Symptoms of the following disorders can be similar to those of ameloblastoma. Comparisons may be useful for a differential diagnosis:
Hard Odontoma is a tumor of dental origin. It is composed of several characteristics of teeth such as enamel, dentin and cement. The Hard Odontoma grows by spreading directly; the ameloblastoma grows by infiltrating other spaces.
Osteosarcoma may often be confused with ameloblastoma. This cancer of the bone differs from the dental tumor by arising from the bone forming cells of the long bones.
Globulomaxillary Cysts are located between the teeth and may cause the teeth to spread apart. The cysts are either oval or heart shaped and may be removed or drained. Sometimes the treatment of the cysts can cause loss of teeth.
Surgical removal of the affected tissue is the preferred treatment. A wide margin of healthy tissue should be removed from the treated area to keep the chance of tumor regrowth to a minimum. If the tumor does reoccur, surgery is performed again.
If there is malignant spread of the tumor, radiation is the treatment choice. Chemotherapy is usually not as effective in these cases.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the National Institutes of Health (NIH) in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Ballenger JJ, ed. Diseases of the Nose, Throat, Ear, Head and Neck. 14th ed. Lea & Febiger, Malvern, PA; 1991:213, 328.
Hicks WL Jr, Myers LL, Winston JS. Rare Pediatric Malignancies of the Head and Neck. In: Raghaven D, Brecher ML, Johnson DH. Textbook of Uncommon Cancer. 2nd ed. John Wiley & Sons. New York, NY; 1999:557-61.
Avon SL, McComb J, Clokie C. Ameloblastic carcinoma: case report and literature review. J Can Dent Assoc. 2003;69:573-76.
Dhir K, Sciubba J, Tufano RP. Ameloblastic carcinoma of the maxilla. Oral Oncol. 2003;39:736-41.
Mosqueda-Taylor A, Carlos-Bregni R, Ramirez-Amador V, et al. Odontoameloblastoma. Clinico-pathologic study of three cases and critical review of the literature. Oral Oncol. 2002;38:800-05.
Zwahlen RA, Gratz KW. Maxillary ameloblastomas: a review of the literature and of a 15-year database. J Craniomaxillofac Surg. 2002;30:273-79.
Ord RA, Blanchaert RH Jr, Nikitakis NG, et al. Ameloblastoma in children. J Oral Maxillofac Surg. 2002;60:762-70, 770-1.
Pillai RS, Ongole R, Ahsan A, et al. Recurrent desmoplastic ameloblastoma of the maxilla: a case report. J Can Dent Assoc. 2004;70:100-104.
Junquera L, Ascani G, Vincente JC, et al. Ameloblastoma revisited. Ann Otol Rhinol Laryngol. 2003;112:1034-39.
Levin MP, Kratochvil FJ, Nolan J. Ameloblastoma of the mandible: a case report. J Periodontal. 2003;74:883-86.
Campbell D, Jeffrey RR, Wallis F, et al. Metastatic pulmonary ameloblastoma. An unusual case. Br J Oral Maxillofac Surg. 2003;41:194-96.
Datta R, Winston JS, Diaz-Reyes G, et al. Ameloblastic carcinoma: report of an aggressive case with multiple bony metastases. Am J Otolaryngol. 2003;24:64-69.
Becelli R, Carboni A, Carulli G, et al. Mandibular ameloblastoma: analysis of surgical treatment carried out in 60 patients between 1977 and 1998. J Craniofac Surg. 2002;13:395-400; 400.
Ciment LM, Ciment AJ. Malignant ameloblastoma metastatic to the lungs 29 years after primary resection: a case report. Chest. 2002;121:1359-61.
Kumamoto H, Ohki K, Ooya K. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. J Oral Pathol Med. 2002;31:28-34.
FROM THE INTERNET
Ameloblastoma. Marquette University School of Dentistry - Oral & Maxillofacial Pathology. nd. 4pp.
Zane RS. Maxillary Ameloblastoma. August 10,1991.
American Cancer Society, Inc.
- 250 Williams NW St
- Ste 6000
- Atlanta, GA 30303
- Tel: (404)320-3333
- Tel: (800)227-2345
- Website: //www.cancer.org
Genetic and Rare Diseases (GARD) Information Center
- PO Box 8126
- Gaithersburg, MD 20898-8126
- Tel: (301)251-4925
- Fax: (301)251-4911
- Tel: (888)205-2311
- Website: //rarediseases.info.nih.gov/GARD/
NIH/National Institute of Dental and Craniofacial Research
- Building 31, Room 2C39
- 31 Center Drive, MSC 2290
- Bethesda, MD 20892
- Tel: (301)496-4261
- Fax: (301)480-4098
- Tel: (866)232-4528
- Email: email@example.com
- Website: //www.nidcr.nih.gov/
Rare Cancer Alliance
- 1649 North Pacana Way
- Green Valley, AZ 85614
- Website: //www.rare-cancer.org
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
For additional information and assistance about rare disorders, please visit the National Organization for Rare Disorders web site at www.rarediseases.org
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report.
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
Last Updated: 4/6/2009
Copyright 2009 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.